1.25Open1.25Pre Close12 Volume0 Open Interest49.50Strike Price1.62KTurnover66.10%IV1.57%PremiumDec 6, 2024Expiry Date0.76Intrinsic Value100Multiplier2DDays to Expiry0.79Extrinsic Value100Contract SizeAmericanOptions Type0.6196Delta0.1346Gamma32.43Leverage Ratio-0.2290Theta0.0021Rho20.09Eff Leverage0.0163Vega
Viking Therapeutics Stock Discussion
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
lets gooooooo
No comment yet